Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18.
Zhuoqun SunYun LanShujia LiangJing WangMingjian NiXia ZhangFengting YuMeiling ChenHanxi ZhangLiting YanWeiping CaiGuanghua LanYe MaFujie ZhangPublished in: The Journal of antimicrobial chemotherapy (2022)
In China, the prevalence of doravirine cross-resistance among patients who have failed first-line ART is high. Therefore, doravirine should not be used blindly without genotypic resistance testing and is not recommended for people who have failed first-line NNRTI-based ART.